Compare CENT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENT | FOLD |
|---|---|---|
| Founded | 1955 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | N/A | 2007 |
| Metric | CENT | FOLD |
|---|---|---|
| Price | $33.31 | $9.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $50.00 | $30.29 |
| AVG Volume (30 Days) | 88.7K | ★ 4.4M |
| Earning Date | 11-24-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.41 | N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $3,129,064,000.00 | $598,704,000.00 |
| Revenue This Year | $2.20 | $21.12 |
| Revenue Next Year | $2.10 | $21.23 |
| P/E Ratio | $13.08 | ★ N/A |
| Revenue Growth | N/A | ★ 21.28 |
| 52 Week Low | $28.77 | $5.51 |
| 52 Week High | $43.88 | $10.57 |
| Indicator | CENT | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 65.69 |
| Support Level | $33.18 | $9.63 |
| Resistance Level | $34.24 | $10.05 |
| Average True Range (ATR) | 1.05 | 0.37 |
| MACD | 0.18 | -0.02 |
| Stochastic Oscillator | 54.15 | 54.40 |
Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.